Loading organizations...
Loading organizations...
HoustonBionics offers ExoRehab X, an AI-powered, at-home exoskeletal device for upper-extremity rehabilitation. It delivers resistance therapy to individuals recovering from stroke and traumatic brain injuries. This device activates neuroplasticity through high-repetition therapy, promoting functional recovery at home, with configurable modules for personalized treatment.
Founded by Ali, Kutay, and Utku Pehlivan, alongside Yagiz Sisman, HoustonBionics originated from Utku Pehlivan’s PhD research at Rice University in rehabilitation robotics. This academic background and clinical understanding inspired accessible, low-cost wearable device development. Their insight was to provide continuous, effective at-home care, extending therapy beyond clinics.
HoustonBionics primarily serves stroke survivors and individuals recovering from traumatic brain injuries. The company envisions advancing neurorehabilitation by delivering sophisticated therapeutic solutions into patients' homes. They empower neurologically impaired individuals with tools for consistent, effective recovery, fostering functional independence and enhancing overall quality of life.
HoustonBionics has raised $400K across 1 funding round.
HoustonBionics has raised $400K in total across 1 funding round.
HoustonBionics has raised $400K in total across 1 funding round.
HoustonBionics has raised $400K across 1 funding round. Most recently, it raised $400K Seed in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $400K Seed |
HoustonBionics is a medical technology company developing the ExoRehab X, a home-based exoskeletal rehabilitation device for upper-extremity therapy targeting patients recovering from strokes or traumatic brain injuries (TBIs).[1][2][3][5] The device supports active movement across five joints—elbow, wrist (ulnar-radial deviation and flexion-extension), shoulder, and forearm—through personalized, AI-powered gamified sessions that track progress via onboard sensors and provide user-friendly reports.[1][5] It serves stroke and TBI survivors, particularly those post-inpatient therapy (even 12+ years after injury), solving the problem of limited access to consistent, engaging rehabilitation by enabling at-home use that improves mobility and functionality without compensatory movements.[1][3][5]
The company has raised over $300K in funding and demonstrates early growth through its focus on neurorehabilitation, backed by a scientific advisory board of experts from academia and clinical practice.[1][4]
Founded in 2019 and based in Sakarya, Turkey, HoustonBionics emerged from a recognition that stroke survivors and TBI patients needed better tools to accelerate recovery and regain independence at home.[2][4] The core idea stemmed from gaps in traditional therapy—many patients sought ways to speed progress beyond clinical settings, leading to the development of fixed-frame upper-body robotics.[2][4] Early traction came via the ExoRehab X prototype, tailored as a "home gym for neuro-recovery," with the company building a community around scientific approaches and expert advisory input.[1][4]
HoustonBionics rides the growing wave of at-home medical exoskeletons and wearable robotics, fueled by post-pandemic demand for remote healthcare and aging populations facing rising stroke/TBI incidences.[1][2][3] Timing aligns with advances in AI for personalized therapy and sensor tech, reducing reliance on costly clinic visits amid clinician shortages.[1][5] Market forces like telehealth expansion and neurorehab funding favor compact, user-friendly devices; HoustonBionics influences the ecosystem by democratizing upper-extremity recovery, potentially setting standards for gamified, data-driven home rehab in the $10B+ exoskeleton market.[2]
HoustonBionics is poised for scale through ExoRehab X commercialization, likely expanding via clinical trials, partnerships with rehab networks, and global distribution from its Turkish base.[1][2] Trends like AI personalization, VR integration, and insurance reimbursement for home devices will propel growth, while regulatory approvals (e.g., FDA/CE marking) could unlock U.S./EU markets.[5] Its influence may evolve from niche neurorecovery player to broader tele-rehab leader, empowering more patients toward independence as exoskeleton adoption surges. This positions HoustonBionics at the intersection of medtech innovation and accessible recovery.